Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    CBRNE

    RFI – Improved Nerve Agent Treatment System

    By Global Biodefense StaffApril 2, 2015
    Nerve and Blister Agent Protective Gear
    Nerve and Blister Agent Protective Gear. Credit: USA.gov
    Share
    Facebook LinkedIn Reddit Email

    The U.S. Department of Defense (DoD) is conducting market research on manufacturing capabilities for the nerve agent antidote scopolamine for intramuscular administration.

    The DoD’s Medical Countermeasure Systems-Chemical Defense Pharmaceuticals (MCS-CDP) Joint Product Management Office is responsible for the development, procurement, fielding, and sustaining of such medical treatments and prophylactic capabilities against chemical, radiological and nuclear threats. The current MCS-CDP portfolio includes nerve agent therapeutics, pretreatments and prophylactics at varying stages of clinical development, including FDA-approved drugs.

    Currently, MCS-CDP is seeking capabilities from interested parties for the advanced development of the centrally-acting therapeutic scopolamine for intramuscular administration by military Service Members for use as an adjunct in conjunction with the pretreatment pyridostigmine bromide (PB) as well as the oxime/atropine and anticonvulsant therapies.

    This Request for Information (RFI) seeks to identify existing sources for the active pharmaceutical ingredient scopolamine hydrobromide, and identify expertise for the development and/or manufacture of the drug product/ substance for FDA approval.

    Further details are available via Solicitation Number: W911QY15S0007. Responses are due by April 8, 2015.

    RFI
    Share. Facebook LinkedIn Reddit Email
    Previous ArticlePositive Safety, Efficacy Results for VSV-EBOV Ebola Vaccine
    Next Article Tetra Tech Awarded EPA National Homeland Security Research Contract

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Terrorism and the Pandemic: Weaponizing a Public Health Crisis

    September 20, 2023

    SOREX Brings Top CBRNE Units to Dugway Proving Ground

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy